SOBI•prnewswire•
Sobi to advance Gamifant® (emapalumab) in interferon-gamma-driven sepsis (IDS) based on EMBRACE topline data
Summary
STOCKHOLM, Jan. 7, 2026 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant® (emapalumab) for interferon-gamma (IFNγ)-driven sepsis (IDS), showed proof-of-concept with observed improvement in organ dysfunction and...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 7, 2026 by prnewswire